Trial Profile
Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 17 Feb 2023 Results of post-hoc analysis of 2 studies (NCT02089256 and NCT03160261) assessing effect of a short-acting and a long-acting GLP-1 RA on GH secretion, published in the Diabetes Therapy.
- 31 Mar 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
- 31 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.